Kyverna Therapeutics (KYTX) director awarded options and RSUs in equity grant

Rhea-AI Filing Summary

Miller Andrew Craig reported acquisition or exercise transactions in this Form 4 filing.

Kyverna Therapeutics director Andrew Craig Miller reported equity awards consisting of a stock option for 42,945 shares and a restricted stock unit grant for 11,006 shares of common stock. The RSUs vest in three equal annual installments, while the option vests monthly over 36 months, in each case subject to continued service.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Miller Andrew Craig

(Last) (First) (Middle)

C/O KYVERNA THERAPEUTICS, INC.

5980 HORTON ST., STE 550

(Street)

EMERYVILLE CA 94608

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kyverna Therapeutics, Inc. [ KYTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/24/2026		A		11,006(1)	A	$0	11,006	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$7.95	02/24/2026		A		42,945		(2)	02/24/2036	Common Stock	42,945	$0	42,945	D

Explanation of Responses:

1. Represents a restricted stock unit award of common stock and 1/3rd of the shares underlying the restricted stock unit award shall vest on each one-year anniversary of the date of grant, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

2. 1/36th of the shares subject to the option shall vest on each monthly anniversary of the date of grant, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

	/s/ Marc Grasso, as Attorney-in-Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Kyverna Therapeutics (KYTX) director Andrew Craig Miller report in this Form 4?

Andrew Craig Miller reported equity awards from Kyverna Therapeutics, including stock options and restricted stock units. These are compensation-related grants, not open-market purchases or sales, and they vest over time based on his continued service to the company.

How many Kyverna Therapeutics (KYTX) stock options were granted to Andrew Craig Miller?

Andrew Craig Miller was granted a stock option covering 42,945 shares of Kyverna Therapeutics common stock. This option was awarded at a price of $0.00 per share as part of his compensation, with vesting tied to a 36‑month service-based schedule.

What restricted stock units did Andrew Craig Miller receive from Kyverna Therapeutics (KYTX)?

He received a restricted stock unit award for 11,006 shares of Kyverna Therapeutics common stock. One-third of these RSUs vest on each one-year anniversary of the grant date, subject to his continuous service through each vesting date with the company.

How do the Kyverna Therapeutics (KYTX) stock options granted to Andrew Craig Miller vest?

The stock options vest in equal monthly installments over 36 months. Specifically, one‑thirty‑sixth of the option shares vest on each monthly anniversary of the grant date, as long as Andrew Craig Miller continues to provide service to Kyverna Therapeutics.

Are the Kyverna Therapeutics (KYTX) Form 4 transactions open-market buys or sells?

No, the transactions reflect equity compensation grants, not open-market trading. The Form 4 shows a stock option grant and a restricted stock unit award, each with a grant price of $0.00 per share, subject to multi-year vesting based on continued service.

What is Andrew Craig Miller’s ownership type for these Kyverna Therapeutics (KYTX) awards?

The awards are reported as held directly by Andrew Craig Miller. The Form 4 indicates direct ownership for both the stock option and the restricted stock unit award, with no footnote disclaiming voting or investment authority over the reported securities.